

Title (en)
NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE

Title (de)
NEUES INDOLDERIVAT MIT HEMMENDER WIRKUNG AUF I-B-KINASE

Title (fr)
NOUVEAU DÉRIVÉ D'INDOLE AYANT UNE ACTIVITÉ INHIBITRICE SUR LA I B KINASE

Publication
EP 2119703 A4 20100825 (EN)

Application
EP 08703206 A 20080115

Priority
• JP 2008050342 W 20080115
• JP 2007005554 A 20070115

Abstract (en)
[origin: EP2119703A1] Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKK² and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKK². In the formula, R 1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R 2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.

IPC 8 full level
C07D 209/42 (2006.01); **A61K 31/404** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/47** (2006.01); **A61P 3/00** (2006.01); **A61P 3/10** (2006.01); **A61P 5/00** (2006.01); **A61P 9/00** (2006.01); **A61P 17/00** (2006.01); **A61P 25/00** (2006.01); **A61P 27/02** (2006.01); **A61P 27/06** (2006.01); **A61P 29/00** (2006.01); **A61P 31/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/06** (2006.01); **A61P 37/08** (2006.01); **A61P 43/00** (2006.01); **C07D 401/04** (2006.01); **C07D 403/04** (2006.01)

CPC (source: EP KR US)
A61K 31/404 (2013.01 - KR); **A61P 3/00** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 5/00** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 17/00** (2018.01 - EP); **A61P 19/02** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 27/02** (2018.01 - EP); **A61P 27/06** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 31/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/02** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **A61P 37/08** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07D 209/42** (2013.01 - EP KR US); **C07D 401/04** (2013.01 - EP US); **C07D 401/12** (2013.01 - EP US); **C07D 403/04** (2013.01 - EP US); **C07D 405/04** (2013.01 - EP US); **C07D 405/12** (2013.01 - EP US); **C07D 409/04** (2013.01 - EP US); **C07D 413/04** (2013.01 - EP US); **C07D 417/04** (2013.01 - EP US)

Citation (search report)
• [A] WO 2005023818 A2 20050317 - AXXIMA PHARMACEUTICALS AG [DE], et al
• [A] WO 2005067923 A1 20050728 - SMITHKLINE BEECHAM CORP [US], et al
• See also references of WO 2008087933A1

Cited by
RU2680100C2; RU2680100C9; US9260378B2; US11021427B2; US10717735B2; WO2012059585A1; US9822109B2; US10501460B2; WO2014145051A1; US9718847B2; US10519177B2; WO2022140326A1; US11661431B2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)
EP 2119703 A1 20091118; **EP 2119703 A4 20100825**; **EP 2119703 B1 20121212**; CA 2674865 A1 20080724; CN 101583598 A 20091118; CN 101583598 B 20120912; DK 2119703 T3 20130114; ES 2397292 T3 20130306; JP 2008195711 A 20080828; JP 5070067 B2 20121107; KR 20090109551 A 20091020; PL 2119703 T3 20130430; RU 2009131031 A 20110227; RU 2470918 C2 20121227; US 2010041628 A1 20100218; US 8193237 B2 20120605; WO 2008087933 A1 20080724

DOCDB simple family (application)
EP 08703206 A 20080115; CA 2674865 A 20080115; CN 200880002272 A 20080115; DK 08703206 T 20080115; ES 08703206 T 20080115; JP 2008005854 A 20080115; JP 2008050342 W 20080115; KR 20097016192 A 20080115; PL 08703206 T 20080115; RU 2009131031 A 20080115; US 44882608 A 20080115